Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of "Buy" by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received an average recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.60.

AMRX has been the subject of a number of recent analyst reports. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Wall Street Zen cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Finally, Barclays raised their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Sei Investments Co. grew its holdings in shares of Amneal Pharmaceuticals by 0.4% during the 1st quarter. Sei Investments Co. now owns 340,816 shares of the company's stock worth $2,710,000 after purchasing an additional 1,355 shares in the last quarter. Amalgamated Bank increased its holdings in Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after buying an additional 1,367 shares during the period. GF Fund Management CO. LTD. lifted its holdings in shares of Amneal Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock worth $66,000 after acquiring an additional 1,428 shares during the period. Xponance Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 16.1% during the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after acquiring an additional 1,828 shares during the period. Finally, MetLife Investment Management LLC increased its stake in Amneal Pharmaceuticals by 2.5% in the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock valued at $750,000 after acquiring an additional 2,297 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Down 0.5%

Shares of AMRX opened at $8.09 on Tuesday. Amneal Pharmaceuticals has a twelve month low of $6.32 and a twelve month high of $9.48. The stock has a market capitalization of $2.54 billion, a P/E ratio of -202.20 and a beta of 1.05. The company has a 50 day moving average of $7.59 and a 200-day moving average of $7.91.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 0.46% and a negative return on equity of 188.26%. The firm had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. On average, sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.